>latest-news

SpyGlass Pharma Strengthens Leadership With Appointment Of Elizabeth O’Farrell To Board Of Directors

Former Eli Lilly executive Liz O’Farrell joins SpyGlass Pharma’s Board as Audit Chair, bringing deep financial and governance expertise.

Breaking News

  • Aug 21, 2025

  • Simantini Singh Deo

SpyGlass Pharma Strengthens Leadership With Appointment Of Elizabeth O’Farrell To Board Of Directors

SpyGlass Pharma, a privately held ophthalmic biotechnology company, announced the appointment of Elizabeth (Liz) O’Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. With a career spanning more than 30 years in the pharmaceutical and biotechnology sectors, Ms. O’Farrell brings deep expertise in strategic planning, financial optimization, regulatory compliance, and corporate governance.


During her long tenure at Eli Lilly, she held several senior executive positions, including General Auditor, Chief Financial Officer of Lilly USA, and Senior Vice President of Policy and Finance. Before her retirement in 2017, she served as Chief Procurement Officer and Head of Global Shared Services, overseeing global operations and large-scale financial initiatives. Over the course of her career, she built extensive experience in accounting, financial reporting, financial planning and analysis, operational finance, and audit, establishing herself as a trusted leader in managing complex financial and regulatory matters.


Patrick Mooney, Chief Executive Officer of SpyGlass Pharma, stated, “Liz’s established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 trials this year. Her prior experience managing multinational organizations and teams nicely complements our existing Board of Directors’ strengths. We look forward to leveraging Liz’s valued insights, guidance and counsel as SpyGlass advances its novel platform to reimagine glaucoma management for patients with glaucoma and other chronic eye conditions.”


Ms. O’Farrell, mentioned, “I am excited to join the SpyGlass Board of Directors as the Company prepares to initiate two pivotal Phase 3 trials in patients with moderate open-angle glaucoma or ocular hypertension. I was immediately impressed by the compelling multi-year data already generated by SpyGlass’ Drug Delivery Platform, and I look forward to utilizing my deep experience across finance and operational functions to support the SpyGlass team as they advance a longer-duration alternative for chronic ophthalmic conditions.”


In addition to her new role with SpyGlass Pharma, Ms. O’Farrell serves as Audit Committee Chair for Karius Inc. and Lensar Inc. She is also Chair of the Board of Geron Corporation, and a board member and member of the audit and compensation committees at Genmab Corporation, where she has contributed to the company’s expansion in the United States.


Ms. O’Farrell earned her Master of Business Administration in Management Information Systems and a Bachelor of Arts in Accounting from Indiana University Bloomington. Her combination of financial acumen, governance experience, and leadership across global organizations is expected to provide valuable oversight and guidance as SpyGlass Pharma continues to advance its mission in ophthalmic innovation.

Ad
Advertisement